AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03533777 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral intravenous catheter placement
Description: The region of the upper extremity in which the IV will be placed will be prepped with chlorhexidine and a proximal elastic tourniquet is applied to the upper arm. A 20 gauge 30 millimeter IV catheter is inserted into an upper extremity vein by an anesthesiologist in either an antegrade or retrograde direction depending on which treatment arm the study subject is randomized to.
Study NCT03533777 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood draw
Description: A 20 milliliter(mL) syringe will be connected to the study IV tubing and used to aspirate 20 mL of blood from the study IV catheter. If 20 mL are unable to be aspirated over a 2 minute time frame, a proximal rubber tourniquet will be applied to the upper arm and the blood draw will be reattempted.This will occur twice throughout the study.
Study NCT03533777 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: A 20 milliliter(mL) syringe will be connected to the study IV tubing and used to aspirate 20 mL of blood from the study IV catheter. If 20 mL are unable to be aspirated over a 2 minute time frame, a proximal rubber tourniquet will be applied to the upper arm and the blood draw will be reattempted.This will occur twice throughout the study.
Study NCT03533777 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral intravenous catheter
Description: A 20 gauge 30 millimeter long BD Insyte(TM) Autoguard(TM) angiocatheter will be used for peripheral intravenous catheter placement as described above.
Study NCT03533777 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral intravenous catheter
Description: A 20 gauge 30 millimeter long BD Insyte(TM) Autoguard(TM) angiocatheter will be used for peripheral intravenous catheter placement as described above.
Study NCT03533777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: To keep open (TKO) infusion of 0.9% normal saline
Description: After placement of the peripheral intravenous catheter, an infusion of 0.9% normal saline will be connected to the catheter and infused at a rate of 20 milliliters per hour to keep open (TKO) for future use by preventing blood clot development within the catheter.
Study NCT03533777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: To keep open (TKO) infusion of 0.9% normal saline
Description: After placement of the peripheral intravenous catheter, an infusion of 0.9% normal saline will be connected to the catheter and infused at a rate of 20 milliliters per hour to keep open (TKO) for future use by preventing blood clot development within the catheter.
Study NCT00119561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Support
Description: Each telephone support group of 5 caregivers and a group leader met 14 times over a year. The hour calls were semi-structured with an educational component and a support component, led by a trained Group Leader. Topics included knowledge of dementia, safety, caregiver health and well being, communication, managing behavioral challenges and caregiver stress and coping.
Study NCT01993771 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery with general anaesthesia.
Study NCT01993771 — intervention group
Intervention type: PROCEDURE
Intervention: Raw EEG
Study NCT03061058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: intraperitoneal and/or intravenous
Study NCT03061058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: intraperitoneal and/or intravenous
Study NCT03061058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: intravenous
Study NCT03061058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: intraperitoneal
Study NCT03061058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: intraperitoneal and/or intravenous
Study NCT03061058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: intraperitoneal and/or intravenous
Study NCT03061058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S1
Description: oral
Study NCT03061058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: oral
Study NCT04334447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Improved primary care HF diagnostics
Description: Reimbursement of natriuretic peptide testing for participating general practitioners (GPs) Audit and feedback in GPs EHR
Study NCT01609088 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Erythritol-containing beverage
Description: Orange flavored beverage containing erythritol
Study NCT02259686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apelin 1mg subcutaneous
Description: single subcutaneous injection of Apelin 1mg subcutaneous
Study NCT02259686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apelin 1mg intravenous
Description: 15 minute intravenous bolus of Apelin 1mg intravenous
Study NCT02259686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apelin 5mg subcutaneous
Description: single subcutaneous injection of Apelin 5mg subcutaneous
Study NCT04334447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart Failure education
Description: Reimbursement of heart failure education for patients at risk. Web-based training for participating general practitioners
Study NCT02259686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apelin 5mg intravenous
Description: 15 minute intravenous infusion of Apelin 5mg intravenous
Study NCT02259686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apelin 10 mg subcutaneous
Description: 24 hour continuous subcutaneous infusion of Apelin 10 mg subcutaneous
Study NCT01606306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daily fluticasone propionate
Description: Flovent® HFA, 44 mcg per inhalation, 2 inhalations twice daily
Study NCT01606306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Singulair®, 4 mg granules or chewable tablets by mouth once daily in the evening
Study NCT04334447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured transitional protocol planning post-discharge care
Description: Checklist-supported discharge protocol for HF patients including telephone contact with patients' general practitioners and a contact with the HF educator
Study NCT01606306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: as-needed fluticasone propionate
Description: Flovent® HFA, 44 mcg per inhalation, 2 inhalations, as needed for asthma symptoms
Study NCT00116935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imatinib mesylate
Description: imatinib 400 mg/day orally qd for 12 months
Study NCT00277368 — intervention group
Intervention type: OTHER
Intervention: A structured questionnaire for seizure-related headache
Description: A structured questionnaire for seizure-related headache
Study NCT00116935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imatinib
Description: imatinib 400 mg/d orally qd for 36 months
Study NCT00116935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib
Description: imatinib 400 mg/d orally qd for 36 months
Study NCT04665674 — intervention group
Intervention type: OTHER
Intervention: Standard of care
Description: Standard of car of pulmonary Langerhans cell histiocytosis (PLCH)
Study NCT04656977 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VR
Description: The proposed intervention will consist in three weekly sessions of 2h focused, respectively, on: (1) gathering information about the loss and psychoeducation about perinatal grief, and introduction to the virtual environment; (2) through the use of the virtual environment, women will be assisted in the elaboration and acceptation of loss; (3) recreate, using the features of the virtual environment (i.e., a series of different virtual landscapes and symbolic elements personalized to each participant as personal pictures, sounds or videos) a new and positive metaphor representing the woman's future life.
Study NCT02859064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide
Description: Administered every 28 days irrespective of when SIR-Spheres is administered. No waiting or adjusting of schedule is required. Lanreotide treatment may continue monthly until disease progression or unacceptable toxicity occurs.
Study NCT02859064 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Y-90 microspheres
Description: To be administered by injection through a trans-femoral catheter into the hepatic artery.
Study NCT02665585 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carotid stenting procedure by carotid stent implantation
Description: Carotid stenting procedure by carotid stent implantation
Study NCT02665585 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid stenting procedure by carotid stent implantation
Description: Carotid stenting procedure by carotid stent implantation
Study NCT04656977 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: The TAU condition is a homogenous standard program proposed by the CERIF at UQO based on group counseling offered to women and men who experienced a perinatal loss.
Study NCT04102020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet: Oral
Study NCT04102020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Subcutaneous (SC) or intravenous (IV) injection
Study NCT04102020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Oral Tablet
Study NCT01547195 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: swim training
Description: Swimming training will be conducted with the implementation of the freestyle. The training will be held a week with 3 X 50 minutes for a period of 12 weeks.~Patients will be monitored by a frequency waterproof. When at the beginning of training are carried out five minutes of heating, followed by 40minutos swimming 5 minutes and cooling at the end of training.
Study NCT01547195 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Training walk
Description: The control group will perform walking exercise outdoors, monitored by a frequency, with the heart rate at anaerobic threshold assessed by cardiopulmonary exercise test.~The training of walking will last 50 minutes, three times per week for 12 weeks.~At the beginning of training, there will be a heating time of 5 minutes, followed by LA walk in cooling for 40 minutes and 5 minutes.
Study NCT00125359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib and bexarotene
Description: Daily Erlotinib 150mg and daily bexarotene oral capsules 400mg.
Study NCT01575054 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: botulinum toxin Type A
Description: Double-Blind Study Phase (12 weeks): On Day 1, botulinum toxin Type A 300 U will be given by intramuscular injections into specified muscles of the lower limb, and an optional dose of 100 U may be injected into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period.
Study NCT01575054 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A
Description: Double-Blind Study Phase (12 weeks): On Day 1, botulinum toxin Type A 300 U will be given by intramuscular injections into specified muscles of the lower limb, and an optional dose of 100 U may be injected into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period.
Study NCT01575054 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Normal Saline
Description: Double-Blind Study Phase (12 weeks): On Day 1, normal saline (placebo) will be given by intramuscular injections into specified muscles of the lower limb, and optional injections may be administered into additional lower limb muscles.
Study NCT03491358 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wright jet nebulizer
Description: Roxon Medi-Tech, Montreal, QC, Canada
Study NCT03491358 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aerogen Solo
Description: Aerogen Ltd., Galway, Ireland
Study NCT03123003 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SonicBone Ultrasound
Description: Bone age assessment by SonicBone Ultrasound. The patient needs to put his/her wrist in 3 positions.
Study NCT03123003 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wrist X-ray
Description: Bone age assessment by Wrist X-ray
Study NCT00459368 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback of patient adherence information
Description: Patient inhaled corticosteroid adherence information is being provided to physicians at clinic sites randomized to the intervention arm. Adherence information is available via electronic prescribing software, and so is available to physicians when writing, renewing, or viewing medications. Physicians at intervention sites also receive standard training in how to interpret adherence metrics and how to intervene on poor adherence.
Study NCT00459368 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control group
Description: Physician practicing at control sites are given standard training in how to intervene on poor adherence, but no patient adherence information is provided to these clinicians via electronic prescribing software.
Study NCT00290693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Orally, 1600mg/m2/day given as (800mg/m2 BID), Days 1 through 14 of 21-day cycle
Study NCT00290693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 30 mg/m2, IV, days 1 and 8 every 3 weeks
Study NCT03647423 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldoxorubicin Hydrochloride
Description: Aldoxorubicin Hydrochloride HCI
Study NCT03647423 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: Recombinant human super agonist interleukin-15 (IL-15) complex
Study NCT03647423 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-051
Description: Ad5 \[E1-, E2b-\]-Brachyury
Study NCT03647423 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-061
Description: Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\]
Study NCT03647423 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6301
Description: Brachyury yeast
Study NCT03647423 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: haNK
Description: haNK™, NK-92 \[CD16.158V, ER IL-2\]
Study NCT03647423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: injection
Study NCT03647423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Injection
Study NCT03647423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Capsules
Study NCT03647423 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SBRT
Description: Stereotactic body radiation therapy
Study NCT03029026 — intervention group
Intervention type: OTHER
Intervention: Baseline assessment
Description: Baseline assessment will include clinical history, Quality of Life Questionnaire (EQ-5D/SF-12), a 6-minute-walk test, blood sampling for haematocrit, renal function, biomarkers (NT-pro-BNP and troponin), and biobanking (also for AL exclusions if scanning positive), a urine sample for biobanking (also for AL exclusions if scanning positive), as well as tests performed as the routine pre-operative work-up (clinical electrocardiogram, blood pressure to estimate global LV afterload, valvulo-arterial impedance).
Study NCT03029026 — intervention group
Intervention type: PROCEDURE
Intervention: Transthoracic echocardiography
Description: Patients will undergo a clinical transthoracic echocardiogram for the assessment of AS severity and diastolic function in line with the British Society of Echocardiography guidance. Simultaneous, optimised 2-chamber, 3-chamber and 4-chamber views will need to be recorded (over 3 cycles) for strain analysis.~Severe AS will be defined using standard echocardiography guidelines in conjunction with MDT consensus.
Study NCT03029026 — intervention group
Intervention type: PROCEDURE
Intervention: 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy
Description: Scanning will use a hybrid SPECT-CT gamma camera after intravenous injection of 700 MBq of DPD (effective dose 4mSv). Acquisition technique: 5-minute (early) and then 3-hour (late) whole body planar scans, followed by SPECT-CT of the heart. Qualitative visual (Perugini) scoring of the cardiac uptake is performed from the 3-hour whole body planar images and the SPECT-CT images.
Study NCT03029026 — intervention group
Intervention type: RADIATION
Intervention: CT 3-5-minute post-contrast research sequences
Description: Cardiac CT for ECV will use the dedicated cardiac CT scanner (Somatom FORCE; Siemens Medical Solutions, Germany). 3-5-minute post contrast research images will be taken at the end of the clinically indicated TAVR work-up CT.
Study NCT03029026 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiac Magnetic Resonance
Description: CMR will be performed using a 1.5-T Aera for standard late gadolinium enhancement, as well as T1 mapping and ECV.
Study NCT03029026 — intervention group
Intervention type: PROCEDURE
Intervention: Endomyocardial biopsy
Description: Septal tissue specimens will be taken under direct vision by the surgical team using a 14-gauge coaxial needle system. Biopsies will be screened for amyloid by Congo red staining; if positive, tissue will be fully sub-typed (immunohistochemistry, mass spectrometry).
Study NCT03029026 — intervention group
Intervention type: OTHER
Intervention: Follow-up assessment
Description: 1-year follow-up with clinical echocardiogram (for sAVR and TAVI patients) and/or telephone interview for all patients (if not carried out in person at the time of the echocardiogram). This will include a follow up Quality of Life Questionnaire as per baseline. If attending clinic or echocardiogram a 6-minute-walk test will also be performed.
Study NCT03797131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KB195 (a novel mixture of oligosaccharides)
Description: KB195 (a novel mixture of oligosaccharides) for oral intake for 21 days.
Study NCT03173495 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FRUCTOSE
Description: Fructose-rich beverage with a high fat meal, without exercise.
Study NCT03173495 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FRUCTOSE
Description: Fructose-rich beverage with a high fat meal, without exercise.
Study NCT03173495 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: DEXTROSE
Description: Dextrose-rich beverage with a high fat meal (control), without exercise.
Study NCT03173495 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EXERCISE
Description: 45 minutes of 60% VO2peak aerobic exercise
Study NCT00538512 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone
Description: single dose licensed trivalent inactivated influenza vaccine (2007-08)
Study NCT00538512 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Flumist
Description: single dose licensed live-attenuated influenza vaccine Flumist (2007-08)
Study NCT00538512 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physiologic saline
Description: single dose placebo administered as an intranasal spray or intramuscular injection
Study NCT02349282 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcifediol 10ug/day
Study NCT02349282 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 20ug/day
Study NCT02349282 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03326518 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lumentin® 44
Description: Contrast agent
Study NCT03326518 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Diluted Omnipaque®
Description: Contrast agent
Study NCT03326518 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Movprep®
Description: Contrast agent
Study NCT03259906 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DASH score
Description: Questionnaire asking about Disability of Arm, Shoulder and Hand
Study NCT03259906 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: X-ray
Description: postoperative x-rays at 6 weeks, 3, 6 and 12 months
Study NCT03259906 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: posterior osteosynthesis
Description: Osteosynthesis using a posterior plate
Study NCT03259906 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior osteosynthesis
Description: Osteosynthesis using an anterior plate
Study NCT02653898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DHA-PIP
Description: Administered monthly (weight-based) on days 1-3, during months 1, 2, and 3 in the MMP arm and also as a first line agent for P.v malaria recurrence in both MMP and FSAT treatment arms